SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Infectious Diseases Consultation — John Henry Holliday
| Patient | John Henry Holliday |
|---|
| Date of birth | 2004-08-14 |
|---|
| Identifiers | MRN HR-NI007-SYN; SSN (made up) 000-07-8153 |
|---|
| Document date | 2026-02-24 |
|---|
| Author | Leticia Navarro, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
New cavitary, smear-positive pulmonary tuberculosis in a 21-year-old dentist who drinks heavily. Please confirm the regimen and doses, advise on liver monitoring given his alcohol use, and advise on isolation, return to dental work, and the length of treatment. [S]
Urgency: Urgent, within two weeks, on the same day as his two-week primary care visit. [S]
Questions for the consultant:
- Do you agree with the regimen and the weight-based doses?
- How should his liver be monitored, given his drinking, and when should the drugs be stopped?
- When can he leave home isolation and return to treating patients?
- How long should treatment last, given the cavity, and is the four-month rifapentine and moxifloxacin regimen an option?
- When can ethambutol be stopped?
- Is any other testing or follow-up needed from infectious diseases?
History of Present Illness
Mr. Holliday, a 21-year-old dentist, is seen at the request of Dr. Beaumont two weeks after a diagnosis of cavitary pulmonary tuberculosis. He has taken all thirteen doses of isoniazid, rifampin, pyrazinamide, and ethambutol with pyridoxine by video-observed therapy. His cough and night sweats are improving and the hemoptysis has stopped. He has mild nausea after the morning doses and orange urine and tears, and no jaundice, abdominal pain, rash, numbness, or vision change. He has cut his drinking down sharply. He has no travel outside the country, no known contact with drug-resistant tuberculosis, and no immune-suppressing condition or medicine. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- John Henry Holliday was born on August 14, 1851, in Griffin, Georgia. [D]
- In 1866 Holliday's mother died of tuberculosis. [D]
- He enrolled at the Pennsylvania College of Dental Surgery in 1870 and graduated in 1872, then practiced dentistry in Atlanta before opening his own practice in Griffin. [D]
- Shortly after beginning his career as a dentist in Atlanta he developed a bad cough; doctors diagnosed tuberculosis and advised a move to a more arid climate. He developed chronic pulmonary tuberculosis. [D]
- He was diagnosed with tuberculosis in 1873 and moved west for a healthier, drier climate, arriving in Dallas, Texas, in September 1873. [D]
- He made his living at the card tables, aggravating his tuberculosis with heavy drinking and late nights. [D]
1 later historical claim is omitted because it describes events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Isoniazid 300 mg tablet, one tablet daily | 300 mg once daily by video-observed therapy with the health department, seven days a week, for six months | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Rifampin 300 mg capsules, two capsules (600 mg) daily | 600 mg once daily on an empty stomach by video-observed therapy with the health department, seven days a week, for six months | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily | 1500 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase | Oral route | 2026-02-12 to 2026-04-08 | completed | S |
| Ethambutol 400 mg tablets, three tablets (1200 mg) daily | 1200 mg once daily by video-observed therapy with the health department, seven days a week, until susceptibility results return | Oral route | 2026-02-12 to 2026-03-10 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed |
A15.0 | S — Synthetic modern coding of his documented pulmonary tuberculosis at the time of diagnosis; the bacteriology is synthetic. |
| Alcohol use disorder, mild, with binge drinking | active | confirmed |
F10.10 | S — Synthetic modern coding anchored to the documented heavy drinking; the severity and the criteria met are synthetic. |
Physical Exam
Vital signs recorded on 2026-02-24; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Thin; temperature 37.3 °C, heart rate 92; seen in a negative-pressure room |
| Eyes | No icterus; visual acuity and color vision normal |
| Respiratory | Coarse crackles and bronchial breathing over the right upper zone |
| Abdomen | Soft, non-tender; liver not enlarged |
| Neurological | Normal sensation in the feet |
| Skin | No rash |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 2026-02-24 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 | U/L | 7-56 U/L | Normal | S |
| 2026-02-24 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 39 | U/L | 10-40 U/L | Normal | S |
| 2026-02-24 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-02-24 | Visual acuity uncorrected Right eye by ETDRS eye chart | 85 | {letters} | >=80 | Normal | S |
| 2026-02-24 | Visual acuity uncorrected Left eye by ETDRS eye chart | 84 | {letters} | >=80 | Normal | S |
| 2026-02-24 | Total score [AUDIT-C] | 4 | {score} | | | S |
Assessment
- Cavitary pulmonary tuberculosis, probably drug-susceptible (A15.0). Smear-positive, culture-positive cavitary disease with an early clinical response and full adherence. No rifampin resistance on the molecular test; isoniazid susceptibility is pending. The regimen and the weight-band doses are correct: isoniazid about 5 mg/kg, rifampin about 10 mg/kg, pyrazinamide 1500 mg and ethambutol 1200 mg for 56 to 75 kg. HIV negative. [S]
- Liver risk. Heavy drinking, low albumin, and the three hepatotoxic drugs together raise his risk of drug-induced liver injury. Today's ALT 41, AST 39, and bilirubin 0.7 are normal. Injury is defined as ALT at least three times the upper limit with symptoms, or at least five times without symptoms, or a bilirubin rise; small rises below this are common and do not need the drugs stopped. [S]
- Infectiousness and return to work. He remains infectious until he has three negative sputum smears, a clinical response, and at least two weeks of effective treatment. Because he works close to patients' faces, return should wait for all three. [S]
- Length of treatment. Six months in total if the two-month culture is negative. A cavity on the first X-ray together with a positive two-month culture would extend the continuation phase to seven months. The four-month rifapentine and moxifloxacin regimen is an alternative only at the start of treatment; switching now offers no benefit. [S]
- Alcohol use disorder, mild (F10.10). Stopping alcohol is the most useful thing he can do for his liver during treatment. If medication is wanted, acamprosate is preferred, because it is not processed by the liver; naltrexone and disulfiram are best avoided while he is on hepatotoxic drugs. [S]
Data reviewed: Dr. Beaumont's diagnostic note; the chest X-ray; the three baseline smears and the nucleic acid amplification result; today's report that the baseline cultures are growing Mycobacterium tuberculosis complex, with susceptibility pending; the HIV, hepatitis B, and hepatitis C results, all negative, with no hepatitis B immunity; and today's liver tests and vision check. [S]
Plan of Treatment
- Continue isoniazid 300 mg, rifampin 600 mg, pyrazinamide 1500 mg, ethambutol 1200 mg, and pyridoxine 50 mg daily by video-observed therapy, seven days a week, for the 56-dose intensive phase; bedtime dosing with a snack for the nausea. [S]
- Stop ethambutol once the isolate is shown to be susceptible to isoniazid and rifampin. [S]
- Visual acuity and color vision monthly while on ethambutol. [S]
- Liver tests monthly throughout treatment because of his drinking, and at once for any nausea, vomiting, abdominal pain, jaundice, or dark urine; the health department nurse should hold doses for those symptoms until results are back. [S]
- Stop all hepatotoxic drugs if ALT reaches three times the upper limit with symptoms, or five times without, and call me. [S]
- Three sputum smears on consecutive mornings in the third week; release from home isolation and return to dental work when all three are negative, with continued clinical improvement. [S]
- Sputum smear and culture monthly until two consecutive cultures are negative, including a culture at the end of the intensive phase. [S]
- Continuation phase of isoniazid and rifampin for four months if the two-month culture is negative, or seven months if it is positive. [S]
- No alcohol during treatment; counseling with a substance-use counselor; acamprosate if medication is wanted. [S]
- Hepatitis B vaccination, which can wait until treatment ends. [S]
- I will review the results by message at two months and at the end of treatment; no infectious diseases visit is needed unless the cultures stay positive, a drug must be stopped, or resistance is found. [S]
- Discussed with Dr. Beaumont, who sees him the same day, and with the health department tuberculosis nurse who supervises his video-observed therapy. The plan, the warning symptoms of liver injury, and the criteria for returning to work were explained to Mr. Holliday, who agreed with them. [S]
- Follow-up: Results review by message at two months and at the end of treatment; sooner for liver injury, persistent positive cultures, or drug resistance. [S]